CD8A and cancer: In preclinical studies of murine models of cancer, LAG-3 and PD1 have been shown to be co-expressed on both CD4+ and CD8+ TILs, and co-blockade of the Lag-3 and PD1 pathways has been shown to synergize to improve antitumor CD8+ T cell responses36.